HAEMONETICS CORP 4
4 · HAEMONETICS CORP · Filed Oct 24, 2014
Insider Transaction Report
Form 4
ALLEN PETER M
Chief Marketing Officer
Transactions
- Award
Performance Shares
2014-10-22+10,071→ 35,071 totalExercise: $0.00From: 2017-09-30Exp: 2017-12-31→ Common Stock (10,071 underlying) - Disposition to Issuer
Common Stock
2014-10-24$35.44/sh−264$9,356→ 34,306 total - Award
Non-Qualified Stock Option (right to buy)
2014-10-22+22,349→ 22,349 totalExercise: $34.74From: 2015-10-22Exp: 2024-10-22→ Common Stock (22,349 underlying) - Award
Common Stock
2014-10-22+5,035→ 34,570 total
Footnotes (4)
- [F1]Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.
- [F2]Pursuant to a 10b5-1 Plan to cover tax liability for released shares.
- [F3]Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.
- [F4]Performance Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Performance Stock Unit based on the performance of Haemonetics stock price relative to the Standard & Poors Health Care Equipment Index. The number of Performance Stock Units (and therefore the number of shares payable) will depend on the Company's stock price performance between October 1, 2014 and September 30, 2017. The Performance Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).